Is It Time To Reassess Danaher (DHR) After Recent Share Price Weakness?

Simply Wall St.03-10

If you are wondering whether Danaher is starting to look attractively priced or still has more room to fall, its recent share performance and valuation checklist provide a useful starting point. The ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618973604?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/265621-main-header/1756203226349","is_english":true,"pubTime":"2026-03-10 08:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618973604","market":"nz","top_or_hot":-1,"title":"Is It Time To Reassess Danaher (DHR) After Recent Share Price Weakness?","media":"Simply Wall St.","content":"<div>\n<p>If you are wondering whether Danaher is starting to look attractively priced or still has more room to fall, its recent share performance and valuation checklist provide a useful starting point. The ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/is-it-time-to-reassess-danaher-dhr-after-recent-share-price\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Time To Reassess Danaher (DHR) After Recent Share Price Weakness?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Time To Reassess Danaher (DHR) After Recent Share Price Weakness?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-10 08:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/is-it-time-to-reassess-danaher-dhr-after-recent-share-price><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you are wondering whether Danaher is starting to look attractively priced or still has more room to fall, its recent share performance and valuation checklist provide a useful starting point. The ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/is-it-time-to-reassess-danaher-dhr-after-recent-share-price\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BQXX3F31.USD","symbol_name":"GUINNESS GLOBAL INNOVATORS \"C\" (USD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/is-it-time-to-reassess-danaher-dhr-after-recent-share-price","article_id":"2618973604","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/265621-main-header/1756203226349"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/is-it-time-to-reassess-danaher-dhr-after-recent-share-price","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2618973604","pubTimestamp":1773102893,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"If you are wondering whether Danaher is starting to look attractively priced or still has more room to fall, its recent share performance and valuation checklist provide a useful starting point.\nThe stock last closed at US$198.80, with returns of a 3.5% decline over 7 days, 8.2% decline over 30 days, 13.7% decline year to date, 2.5% decline over 1 year, 5.3% decline over 3 years, and a 5.6% gain over 5 years.\nRecent coverage has focused on Danaher as a large US healthcare and life sciences...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BQXX3F31.USD":"GUINNESS GLOBAL INNOVATORS \"C\" (USD) ACC","DHR":"丹纳赫","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU0187121727.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) INC","LU0820562030.AUD":"ALLIANZ INCOME AND GROWTH \"AMH2\" (AUDHDG) H2 INC","LU2063271972.USD":"富兰克林创新领域基金","LU2211814178.USD":"ALLIANZ CLEAN PLANET \"AT\" (USD) ACC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU2244417387.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) ACC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU2125910336.SGD":"Natixis Thematics Water R/A SGD","LU2355687059.USD":"NORDEA 1 GLOBAL IMPACT  \"BP\" (USD) ACC","BK4581":"高盛持仓","LU1923621640.USD":"Natixis Thematics Water R/A USD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","DHR.AU":"Dark Horse Resources","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK4585":"ETF&股票定投概念","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU1917777945.USD":"安联专题基金Cl AT Acc","LU0289961442.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (SGD) ACC","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU1923622614.USD":"Natixis Thematics Meta R/A USD","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LU0109391861.USD":"富兰克林美国机遇基金A Acc","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0312595415.SGD":"Schroder ISF Global Climate Change Equity A Acc SGD","LU0122379950.USD":"贝莱德世界健康科学A2","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU0390134368.USD":"FRANKLIN GLOBAL GROWTH \"A\" (USD) ACC","BK4504":"桥水持仓","IE00BQXX3D17.EUR":"GUINNESS GLOBAL INNOVATORS \"C\" (EUR) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","LU0511384066.AUD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (AUDHDG) ACC","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","BK4588":"碎股","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","IE00BQXX3C00.GBP":"GUINNESS GLOBAL INNOVATORS \"C\" (GBP) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0289960550.SGD":"AB FCP I - GLOBAL EQUITY BLEND PORTFOLIO 'A' (SGD) ACC"},"translate_title":"在最近股价疲软之后，是时候重新评估丹纳赫（DHR）了吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"DHR":1.5,"DHR.AU":1.5},"content_text":"If you are wondering whether Danaher is starting to look attractively priced or still has more room to fall, its recent share performance and valuation checklist provide a useful starting point. The stock last closed at US$198.80, with returns of a 3.5% decline over 7 days, 8.2% decline over 30 days, 13.7% decline year to date, 2.5% decline over 1 year, 5.3% decline over 3 years, and a 5.6% gain over 5 years. Recent coverage has focused on Danaher as a large US healthcare and life sciences group that sits at the crossroads of diagnostics, scientific research tools, and biopharma services. This positioning can influence how investors think about its long-term role in healthcare. Commentary has also highlighted how broader sentiment toward healthcare tools and services companies can feed into Danaher's share price moves, as investors reassess long-term demand and risk. On our framework, Danaher currently scores a 2 out of 6 valuation score. This means some checks flag potential undervaluation while others point to a fuller price. Next, we look at what different valuation methods indicate about that mix, before finishing with a way to place those numbers in a broader investment story.  Danaher scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown. AdvertisementApproach 1: Danaher Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow, or DCF, model estimates what a company might be worth today by projecting its future cash flows and then discounting those back into current dollars. It focuses on the cash the business could generate for shareholders over time. For Danaher, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The company’s last twelve month free cash flow is about $5.1b. Analyst inputs and Simply Wall St extrapolations project free cash flow out to 2035, with 2035 FCF estimated at $10.5b and intermediate years such as 2026 and 2029 at $5.8b and $7.7b respectively, all in $. These future figures are then discounted back, using the model’s required return, to arrive at today’s estimate of value per share. On this basis, the DCF model produces an estimated intrinsic value of about $224.71 per share, compared with the recent share price of $198.80. That gap implies an intrinsic discount of roughly 11.5%, which indicates the stock is trading below this model’s estimate of fair value. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests Danaher is undervalued by 11.5%. Track this in your watchlist or portfolio, or discover 47 more high quality undervalued stocks. DHR Discounted Cash Flow as at Mar 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Danaher. Approach 2: Danaher Price vs Earnings For a profitable company like Danaher, the P/E ratio is a useful way to think about what you are paying for each dollar of current earnings. It links the share price directly to the business’s earnings power. What counts as a “normal” or “fair” P/E depends on how the market views a company’s growth prospects and risk. Higher expected growth or lower perceived risk can support a higher multiple, while lower growth or higher risk usually points to a lower one. Danaher currently trades on a P/E of 39.05x. That sits above the Life Sciences industry average of 32.72x and the peer average of 30.63x, so on simple comparisons the stock looks more expensive than many peers. Simply Wall St’s Fair Ratio framework goes a step further. It estimates what a more tailored P/E might be for Danaher, at 31.30x, by factoring in elements such as earnings growth, profit margins, industry, market cap and risk. Because it is specific to the company, this approach can be more informative than relying only on broad industry or peer averages. Comparing the current 39.05x P/E with the 31.30x Fair Ratio suggests Danaher trades above this model’s view of fair value. Result: OVERVALUED NYSE:DHR P/E Ratio as at Mar 2026 P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies. Upgrade Your Decision Making: Choose your Danaher Narrative Earlier we mentioned that there is an even better way to think about valuation. On Simply Wall St that starts with Narratives, where you set out your own story for Danaher, link it to a forecast for revenue, earnings and margins, and then compare the fair value that follows with the current price, all inside an easy to use tool on the Community page that millions of investors already use. A Narrative is simply your view of what is really driving the business, captured in plain language and then backed up by numbers so you are not just reacting to a single P/E or price target but seeing how your assumptions translate into an explicit value. Because Narratives on the platform update when new information arrives, such as news on the Masimo deal, earnings or changes in analyst expectations, your fair value line can shift automatically while you stay focused on whether the gap between price and value still supports your thesis. With Danaher, for example, one investor might build a Narrative close to the most optimistic analyst view, using a fair value near US$310, while another might anchor on the cautious end around US$205. The power of the tool is that both can see exactly which assumptions create those different outcomes and then decide, in their own time, whether the current share price justifies acting or waiting. Do you think there's more to the story for Danaher? Head over to our Community to see what others are saying! NYSE:DHR 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618973604","isCrawlerRequest":true}